« Back
Home /
Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified)

Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein (MALS & SPR verified)

Item no.	HL1-H52E7-25ug
Manufacturer	ACROBiosystems
Amount	25 ug
Quantity options	200 ug 25 ug
Category	Peptides & Proteins Recombinant Proteins
Type	Proteins Recombinant
Format	Solid
Specific against	Human (Homo sapiens)
Host	HEK293
Conjugate/Tag	Unconjugated
Purity	90%
NCBI	AAA59606.1 (HLA-A*02:01), NP_004039.1 (B2M)
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	NY-ESO-1
Shipping Condition	Room temperature
Available
Manufacturer - Category	Protein
Manufacturer - Conjugate / Tag	C-10xHis, Unconjugated
Shipping Temperature	RT
Storage Conditions	-20°C
Molecular Weight	36.3 kDa, 13.8 kDa and 13.3 kDa
Manufacturer - Format	Powder
Description	NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.
Background	NY-ESO-1, which is also well-known as New York esophageal squamous cell carcinoma 1, is an efficient target for cancer immunotherapy. This antigen is a member of cancer-testis antigens (CTAs) and is highly expressed in various cancers, including melanoma, ovarian, cervical cancer, etc. Adoptive T cell therapy with HLA-A2 restricted NY-ESO-1 transduced CD8+ T cells has improved the clinical response rates and overall survival of treatment-refractory melanoma patients. The Human HLA-A0201 NY-ESO-1 (SLLMWITQV) complex protein is a complex of HLA-A0201 of the MHC Class I, B2M and SLLMWITQV peptide of the NY-ESO-1.
Molecule	HLA-A*02:01 & B2M & NY-ESO-1 (SLLMWITQV)
Exp Region	Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLLMWITQV peptide
Characteristics	Human HLA-A02:01&B2M&NY-ESO-1 (SLLMWITQV) Tetramer Protein is assembled by biotinylated monomer (HL1-H82E4) and streptavidin. Biotinylated Human HLA-A02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein is produced by co-expression of HLA and B2M loaded with NY-ESO-1 peptide. Biotinylated Human HLA-A*02:01&B2M&NY-ESO-1 (SLLMWITQV) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™). The protein has a calculated MW of 36.3 kDa, 13.8 kDa and 13.3 kDa. The protein migrates as 42-45 kDa, 15 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin	1.0 EU per μg
Buffer	PBS, pH7.4
Stability	● -20°C to -70°C for 12 months in lyophilized state ● -70°C for 3 months under sterile conditions after reconstitution._x000D_For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Protectant	trehalose

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

HL1-H52E7-25ug-datasheet.pdf

HL1-H52E7-25ug-safety-datasheet.pdf